UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 670

Sortiert nach

Arsenic trioxide and all- trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

The lancet oncology, 2015-10, Vol.16 (13), p.1295-1305

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Minimal Residual Disease in Standard-Risk AML

The New England journal of medicine, 2016-02, Vol.374 (5), p.422-433

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4123-4131

2013

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Blood, 2012-10, Vol.120 (14), p.2826-2835

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3360-3368

2013

Link zum Volltext

Verfügbarkeit prüfen

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Journal of clinical oncology, 2018-05, Vol.36 (15), p.1486-1497

2018

Link zum Volltext

Verfügbarkeit prüfen

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3924-3931

2012

Link zum Volltext

Verfügbarkeit prüfen

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Journal of clinical oncology, 2011-02, Vol.29 (4), p.369-377

2011

Link zum Volltext

Verfügbarkeit prüfen

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

Journal of clinical oncology, 2013-04, Vol.31 (10), p.1293-1301

2013

Link zum Volltext

Verfügbarkeit prüfen

Statistical reporting in the BJH: some dos and don'ts

British journal of haematology, 2017-02, Vol.176 (3), p.345-351

Hills, Robert K.

2017

Link zum Volltext

Verfügbarkeit prüfen

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

Blood, 2011-07, Vol.118 (2), p.409-412

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2739-2747

2010

Link zum Volltext

Verfügbarkeit prüfen

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

Blood, 2011-05, Vol.117 (18), p.4726-4735

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

Haematologica (Roma), 2022-07, Vol.107 (7), p.1518-1527

2022

Link zum Volltext

Verfügbarkeit prüfen

Independent prognostic factors for AML outcome

Hematology, 2009, Vol.2009 (1), p.385-395

2009

Link zum Volltext

Verfügbarkeit prüfen

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3650-3658

2009

Link zum Volltext

Verfügbarkeit prüfen

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2674-2681

2010

Link zum Volltext

Verfügbarkeit prüfen

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Haematologica (Roma), 2016-11, Vol.101 (11), p.1351-1358

2016

Link zum Volltext

Verfügbarkeit prüfen

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice

Blood, 2018-02, Vol.131 (6), p.636-648

2018

Link zum Volltext

Verfügbarkeit prüfen

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

Journal of clinical oncology, 2010-02, Vol.28 (4), p.586-595

2010

Link zum Volltext

Verfügbarkeit prüfen

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

British journal of haematology, 2023-11, Vol.203 (3), p.353-354

Hills, Robert K.

2023

Link zum Volltext

Verfügbarkeit prüfen

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Blood, 2013-03, Vol.121 (13), p.2424-2431

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 670

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(651)
Mit Volltextzugriff
(611)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(517)
Humans
(472)
Life Sciences & Biomedicine
(323)
Female
(284)
Male
(270)
Middle Aged
(210)
Adult
(185)
Science & Technology - Other Topics
(185)
Multidisciplinary Sciences
(184)
Aged
(162)
Patients
(118)
Treatment Outcome
(111)
Clinical Trials
(109)
Medicine And Health Sciences
(109)
Studies
(103)
Hematology
(101)
Adolescent
(97)
Analysis
(84)
Biology And Life Sciences
(84)
Biological And Medical Sciences
(81)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(173)
Blood
(107)
British Journal Of Haematology
(40)
The New England Journal Of Medicine
(21)
Journal Of Clinical Oncology
(19)
Nature
(11)
Journal Of Neurosurgery
(10)
Pediatric Critical Care Medicine
(10)
New England Journal Of Medicine
(8)
Pediatrics
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Arsenic trioxide and all- trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Assessment of Minimal Residual Disease in Standard-Risk AML

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

Statistical reporting in the BJH: some dos and don'ts

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

Independent prognostic factors for AML outcome

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice

Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape

Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

Suchergebnisse filtern